TAK-925

DRUG5 trials

Sponsors

Takeda, Millennium Pharmaceuticals, Inc.

Conditions

Healthy ParticipantsHealthy Participants and Patients With NarcolepsyHealthy VolunteersIdiopathic HypersomniaNarcolepsyObstructive Sleep Apnea

Phase 1

Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy

CompletedNCT03332784

TakedaHealthy Participants and Patients With Narcolepsy

Start: 2017-11-04End: 2018-09-04Updated: 2021-03-30

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

CompletedNCT03522506

TakedaHealthy Volunteers

Start: 2018-05-09End: 2018-11-07Updated: 2021-03-26

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy

CompletedNCT03748979

TakedaHealthy Participants, Narcolepsy

Start: 2018-11-21End: 2019-10-24Updated: 2020-12-08

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

CompletedNCT04091425

Millennium Pharmaceuticals, Inc.Obstructive Sleep Apnea

Start: 2019-11-21End: 2020-04-02Updated: 2020-04-20

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

CompletedNCT04091438

Millennium Pharmaceuticals, Inc.Idiopathic Hypersomnia

Start: 2020-01-26End: 2020-11-23Updated: 2023-09-26

Related Papers

Orexin 2 receptor‐selective agonist danavorexton (<scp>TAK</scp>‐925) promotes wakefulness in non‐human primates and healthy individuals

Journal of Sleep Research2023-03-1926 citations

Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia

SLEEP2023-03-0812 citations

Safety and pharmacodynamics of a single infusion of TAK-925 in adults with idiopathic hypersomnia (S1.009)

Neurology2022-05-03

Safety and efficacy of TAK-925 in adults with obstructive sleep apnea who experience excessive daytime sleepiness despite adequate use of CPAP (4278)

Neurology2021-04-132 citations